Y Intercept Hong Kong Ltd Takes Position in Repligen Co. (NASDAQ:RGEN)

Y Intercept Hong Kong Ltd purchased a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 4,421 shares of the biotechnology company's stock, valued at approximately $658,000.

Several other large investors also recently made changes to their positions in RGEN. Champlain Investment Partners LLC boosted its position in shares of Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company's stock worth $211,464,000 after buying an additional 850,345 shares during the period. Bank of New York Mellon Corp boosted its position in Repligen by 21.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company's stock worth $172,749,000 after acquiring an additional 237,884 shares during the period. Conestoga Capital Advisors LLC grew its stake in Repligen by 26.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company's stock valued at $119,363,000 after acquiring an additional 199,322 shares in the last quarter. Thrivent Financial for Lutherans increased its holdings in shares of Repligen by 6.1% in the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company's stock valued at $95,037,000 after purchasing an additional 36,773 shares during the period. Finally, DF Dent & Co. Inc. lifted its position in shares of Repligen by 31.0% in the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company's stock worth $87,852,000 after purchasing an additional 139,615 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on RGEN. StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research note on Friday, November 22nd. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Wells Fargo & Company initiated coverage on Repligen in a report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price target for the company. Finally, Wolfe Research initiated coverage on Repligen in a report on Thursday, November 14th. They issued a "peer perform" rating on the stock. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $190.25.

Repligen Price Performance

Shares of RGEN traded up $0.42 during mid-day trading on Friday, reaching $156.41. The company had a trading volume of 466,370 shares, compared to its average volume of 592,662. The company has a market capitalization of $8.76 billion, a P/E ratio of -422.72, a P/E/G ratio of 4.64 and a beta of 0.96. The company's 50-day moving average is $142.66 and its 200-day moving average is $141.59. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating analysts' consensus estimates of $0.34 by $0.09. The firm had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.23 earnings per share. On average, equities analysts anticipate that Repligen Co. will post 1.54 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.